These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22913593)

  • 1. The Oligonucleotide Safety Working Group (OSWG).
    Schubert D; Levin AA; Kornbrust D; Berman CL; Cavagnaro J; Henry S; Seguin R; Ferrari N; Shrewsbury SB
    Nucleic Acid Ther; 2012 Aug; 22(4):211-2. PubMed ID: 22913593
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety signal dampens reception for mipomersen antisense.
    Kling J
    Nat Biotechnol; 2010 Apr; 28(4):295-7. PubMed ID: 20379153
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact and interpretation of multiple guidelines and consensus documents.
    Frohlich ED
    J Hum Hypertens; 1996 Feb; 10 Suppl 1():S63-7. PubMed ID: 8965293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials, consensus conferences, and clinical practice.
    Sniderman AD
    Lancet; 1999 Jul; 354(9175):327-30. PubMed ID: 10440326
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug development. Lupus drug company asks FDA for second chance.
    Couzin J
    Science; 2005 Feb; 307(5711):835. PubMed ID: 15705822
    [No Abstract]   [Full Text] [Related]  

  • 8. Meeting report: oligonucleotide ADME workshop.
    Hood S; Kenworthy D; Christensen JK
    Xenobiotica; 2022 Aug; 52(8):957-961. PubMed ID: 36093882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods for formulating recommendations for clinical practice].
    Dosquet P; Matillon Y
    J Radiol; 1995 Nov; 76(11):1004-6. PubMed ID: 8594173
    [No Abstract]   [Full Text] [Related]  

  • 10. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic applications of oligonucleotides.
    Crooke ST
    Biotechnology (N Y); 1992 Aug; 10(8):882-6. PubMed ID: 1280444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy briefs.
    Philippidis A
    Hum Gene Ther; 2012 Dec; 23(12):1221-3. PubMed ID: 23234557
    [No Abstract]   [Full Text] [Related]  

  • 13. Practice guidelines and practical judgement: the role of mega-trials, meta-analysis and consensus.
    Charlton BG
    Br J Gen Pract; 1994 Jul; 44(384):290-1. PubMed ID: 8068372
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing unintended hybridization-induced biological effects of oligonucleotides.
    Lindow M; Vornlocher HP; Riley D; Kornbrust DJ; Burchard J; Whiteley LO; Kamens J; Thompson JD; Nochur S; Younis H; Bartz S; Parry J; Ferrari N; Henry SP; Levin AA
    Nat Biotechnol; 2012 Oct; 30(10):920-3. PubMed ID: 23051805
    [No Abstract]   [Full Text] [Related]  

  • 15. Strategies for designing clinical trials for oligonucleotide therapeutics.
    Wacheck V
    Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Online consensus conferences for clinical guidelines development - a survey among participants from the International Guidelines for the Treatment of Actinic Keratosis.
    Werner RN; Jacobs A; Rosumeck S; Nast A
    J Eval Clin Pract; 2014 Dec; 20(6):853-6. PubMed ID: 24799003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
    Piana C; Kliphuis E; Della Pasqua O
    Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials, consensus conferences, and clinical practice.
    Thornton H
    Lancet; 1999 Sep; 354(9183):1037. PubMed ID: 10501400
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.
    Alton EW; Boushey HA; Garn H; Green FH; Hodges M; Martin RJ; Murdoch RD; Renz H; Shrewsbury SB; Seguin R; Johnson G; Parry JD; Tepper J; Renzi P; Cavagnaro J; Ferrari N
    Nucleic Acid Ther; 2012 Aug; 22(4):246-54. PubMed ID: 22809313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.